Seroatlas · Human Serome Atlas

RFX5

DNA-binding protein RFX5

Also known as: RFX5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P48382
Gene
RFX5
Ensembl
ENSG00000143390
Chromosome
1
Canonical length
616 aa
Protein class
Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
Subcellular location
Nucleoplasm,Vesicles
Quaternary structure
Homodimer

OverviewNCBI Gene

A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS; MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

616 residues, UniProt reviewed canonical sequence.

>P48382|RFX5
     1  MAEDEPDAKS PKTGGRAPPG GAEAGEPTTL LQRLRGTISK AVQNKVEGIL QDVQKFSDND
    61  KLYLYLQLPS GPTTGDKSSE PSTLSNEEYM YAYRWIRNHL EEHTDTCLPK QSVYDAYRKY
   121  CESLACCRPL STANFGKIIR EIFPDIKARR LGGRGQSKYC YSGIRRKTLV SMPPLPGLDL
   181  KGSESPEMGP EVTPAPRDEL VEAACALTCD WAERILKRSF SSIVEVARFL LQQHLISARS
   241  AHAHVLKAMG LAEEDEHAPR ERSSKPKNGL ENPEGGAHKK PERLAQPPKD LEARTGAGPL
   301  ARGERKKSVV ESSAPGANNL QVNALVARLP LLLPRAPRSL IPPIPVSPPI LAPRLSSGAL
   361  KVATLPLSSR AGAPPAAVPI INMILPTVPA LPGPGPGPGR APPGGLTQPR GTENREVGIG
   421  GDQGPHDKGV KRTAEVPVSE ASGQAPPAKA AKQDIEDTAS DAKRKRGRPR KKSGGSGERN
   481  STPLKSAAAM ESAQSSRLPW ETWGSGGEGN SAGGAERPGP MGEAEKGAVL AQGQGDGTVS
   541  KGGRGPGSQH TKEAEDKIPL VPSKVSVIKG SRSQKEAFPL AKGEVDTAPQ GNKDLKEHVL
   601  QSSLSQEHKD PKATPP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RFX5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.63
Highest tissue expression
67 nTPM

Expression across tissuesHPA

Tissue

  • tonsil: 67 nTPM
  • lymph node: 63 nTPM
  • spleen: 48 nTPM
  • thymus: 47 nTPM
  • appendix: 41 nTPM
  • duodenum: 30 nTPM

Single-cell type

  • late spermatids: 30 nCPM
  • late primary spermatocytes: 29 nCPM
  • kupffer cells: 26 nCPM
  • epididymal basal cells: 24 nCPM
  • gastric progenitor cells: 23 nCPM
  • epididymal clear cells: 23 nCPM

Immune cell

  • naive B-cell: 54 nTPM
  • memory B-cell: 48 nTPM
  • myeloid DC: 47 nTPM
  • NK-cell: 32 nTPM
  • non-classical monocyte: 31 nTPM
  • T-reg: 29 nTPM

Brain region

  • pons: 34 nTPM
  • cerebellum: 33 nTPM
  • midbrain: 32 nTPM
  • medulla oblongata: 31 nTPM
  • hypothalamus: 31 nTPM
  • thalamus: 29 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about RFX5.

Disease | AllUniProt

Conditions RFX5 is implicated in, by any mechanism.

Disease | GeneticClinVar

51 pathogenic / likely-pathogenic of 475 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.1
gnomAD pLI
0
gnomAD missense Z
0.48
DepMap mean gene effect
-0.25
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RFX5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RFX5 as an antibody target. Whether an autoantibody or antibody against RFX5 could matter depends on whether native RFX5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RFX5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label RFX5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/RFX5. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...